MedTrace Logo

HCV Treatment in HIV Co-Infected Patients in Asia

NCT01838772 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2016-10-27

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness and tolerability of hepatitis C virus (HCV) treatment in HIV co-infected patients in routine health care services in Asia through a pilot model of care for treatment of HCV in resource-limited settings.

Conditions

  • Hepatitis C
  • HIV

Interventions

DRUG

Pegylated-Interferon and Ribavirin

This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.

Sponsors & Collaborators

  • Kirby Institute

    collaborator OTHER_GOV

  • amfAR, The Foundation for AIDS Research

    lead OTHER

Principal Investigators

  • Nicolas Durier, MD, MPH · TREAT Asia/ amfAR - The Foundation for AIDS Research

  • Gail Matthews, MD, PhD · Kirby Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-06-30
Completion
2016-09-30

Countries

  • Indonesia
  • Malaysia
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838772 on ClinicalTrials.gov